GlassScriptPhysician profile
Howard Katzenstein
NPI 1316969512
$11,981.51
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $43.34 · 2022: $12K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $11,717.62 | 2022 | |
| Alexion Pharmaceuticals, INC. | $68.71 | 2019 | |
| Novo Nordisk INC | $65.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $47.10 | 2019 | |
| Servier Pharmaceuticals LLC | $42.79 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $14.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.71 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Katzenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.